THE LAB IS MAINLY FOCUSING ON THE FOLLOWING TOPICS

A) HEALTHY EXPANSION OF WHITE ADIPOSE TISSUE (WAT).

WAT is a critical metabolic organ that contributes to energy storage, endocrine homeostasis and metabolic flexibility by efficiently storing surplus fuel and quickly mobilising lipids/energy to supply peripheral organs. In the context of obesity, we are not asking why obese patients develop comorbidities, but rather how to make them resilient and promote healthy expansion in the face of comorbidities. We hypothesise that this depends on the mechanisms that keep adipose tissue healthy regardless of its size.

To answer this question, we will:

  • Identify genetic variants associated with an increased risk of obesity that also have protective cardiometabolic effects, and viceversa.
  • Prioritise and genetically mutate candidate genes using adipocyte cellular models.
  • Validate the functionality of the candidate genes in vitro and in vivo.

B) BROWN ADIPOSE TISSUE (BAT) RECRUITMENT AND ACTIVATION

Using the same approaches indicated for WAT, we will also identify the molecular mechanisms controlling energy expenditure via sympathetic tone to BAT, as well as directly regulating its activation in both the mouse and human contexts.

C) ENDOCRINE DISRUPTING CHEMICAL (EDC) IMPACT ON MASLD PROGRESSION

We have recently added a new area of interest to our research, namely understanding how the exposome, particularly in the form of EDCs, affects the progression of MASLD, a condition that is often linked to obesity.

PRESENTATION

GET TO KNOW US BETTER

  • Own scientific image of the laboratory
  • Own scientific image of the laboratory

RESEARCH STAFF

THE PEOPLE WHO MAKE IT ALL POSSIBLE

Stefania Carobbio 
scarobbio@cipf.es

Maria Martín Grau
mmartin@cipf.es

Mª Carmen Navarro González
cnavarrog@cipf.es

Alicia Enriquez De Salamanca Soto
aenriquez@cipf.es

Cristina Andreea Sanduc 
casanduc@cipf.es

Jaime Navarro Pérez
jnavarro@cipf.es

PUBLICATIONS

OUR SCIENTIFIC CONTRIBUTIONS

Adipose Tissue Dysfunction Determines Lipotoxicity and Triggers the Metabolic Syndrome: Current Challenges and Clinical Perspectives.

Carobbio S, Pellegrinelli V and Vidal-Puig A

Advances in Experimental Medicine and Biology 2024 Jan,  DOI:  10.1007/978-3-031-63657-8_8,  Vol. 1460,  pag. 231-272

READ PUBLICATION

Adipose tissue-derived stem cells, in vivo and in vitro models for metabolic diseases.

Navarro-Perez J and Carobbio S

BIOCHEMICAL PHARMACOLOGY 2024 Apr,  DOI:  10.1016/j.bcp.2024.116108,  Vol. 222,  pag. 116108-116108

READ PUBLICATION

Recent developments in adipose tissue-secreted factors and their target organs.

Navarro-Perez J, Vidal-Puig A and Carobbio S

CURRENT OPINION IN GENETICS & DEVELOPMENT 2023 Jun,  DOI:  10.1016/j.gde.2023.102046,  Vol. 80,  pag. 102046-102046

READ PUBLICATION

Unraveling the Developmental Roadmap toward Human Brown Adipose Tissue

S. CAROBBIO, A. GUENANTIN, M. BAHRI, S. RODRIGUEZ-FDEZ, F. HONIG, I. KAMZOLAS, I. SAMUELSON, K. LONG, S. AWAD, D. LUKOVIC, S. ERCEG, A. BASSETT, S. MENDJAN, L. VALLIER, B. ROSEN, D. CHIARUGI and A. VIDAL-PUIG

Stem Cell Reports 2021 Mar,  DOI:  10.1016/j.stemcr.2021.01.013,  Vol. 16,  pag. 641-655

READ PUBLICATION

Genome-wide discovery of genetic loci that uncouple excess adiposity from its comorbidities.

Huang LO, Rauch A, Mazzaferro E, Preuss M, Carobbio S, Bayrak CS, Chami N, Wang Z, Schick UM, Yang N, Itan Y, Vidal-Puig A, den Hoed M, Mandrup S, Kilpeläinen TO and Loos RJF

Nature Metabolism 2021 Feb,  DOI:  10.1038/s42255-021-00346-2,  Vol. 3,  pag. 228-243

READ PUBLICATION

FUNDING

THANK YOU FOR SUPPORTING US